The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen

doi:10.2337/diabetes.51.3.797

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Identifier:nobleid.org/w1/20260515/099343F9

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/099343F9.svg?ark=w1%2F20260515%2F099343F9)](https://nobleid.org/work/w1/20260515/099343F9)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Identifier:nobleid.org/w1/20260515/099343F9

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/099343F9.svg?ark=w1%2F20260515%2F099343F9)](https://nobleid.org/work/w1/20260515/099343F9)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work